These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31322031)

  • 21. Clinical markers of early disease in persons near onset of Huntington's disease.
    Paulsen JS; Zhao H; Stout JC; Brinkman RR; Guttman M; Ross CA; Como P; Manning C; Hayden MR; Shoulson I;
    Neurology; 2001 Aug; 57(4):658-62. PubMed ID: 11524475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is non-recognition of choreic movements in Huntington disease always pathological?
    Justo D; Charles P; Daunizeau J; Delmaire C; Gargiulo M; Hahn-Barma V; Naccache L; Durr A
    Neuropsychologia; 2013 Mar; 51(4):748-59. PubMed ID: 23262076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apathy Profile in Parkinson's and Huntington's Disease: A Comparative Cross-Sectional Study.
    Sousa M; Moreira F; Jesus-Ribeiro J; Marques I; Cunha F; Canário N; Freire A; Januário C
    Eur Neurol; 2018; 79(1-2):13-20. PubMed ID: 29131091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring the functional impact of cognitive impairment in Huntington's disease.
    Horta-Barba A; Martínez-Horta S; Pérez-Pérez J; Sampedro F; Puig-Davi A; Pagonabarraga J; Kulisevsky J
    J Neurol; 2022 Jul; 269(7):3541-3549. PubMed ID: 35061089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between impairment of voluntary movements and cognitive impairment in Huntington's disease.
    Klempír J; Klempírová O; Stochl J; Spacková N; Roth J
    J Neurol; 2009 Oct; 256(10):1629-33. PubMed ID: 19449086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complex movement behaviour and progression of Huntington's disease.
    Andrich J; Saft C; Ostholt N; Müller T
    Neurosci Lett; 2007 Apr; 416(3):272-4. PubMed ID: 17321683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of impulsivity and inhibitory control deficits in the saccadic behavior of premanifest Huntington's disease individuals.
    Júlio F; Caetano G; Januário C; Castelo-Branco M
    Orphanet J Rare Dis; 2019 Nov; 14(1):246. PubMed ID: 31703597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Self-awareness of deficits in Huntington's and Parkinson's disease].
    Sitek EJ; Sławek J; Wieczorek D
    Psychiatr Pol; 2008; 42(3):393-403. PubMed ID: 19899567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive Dysfunction Contributes to Mobility Impairments in Huntington's Disease.
    Kloos AD; Kegelmeyer DA; Fritz NE; Daley AM; Young GS; Kostyk SK
    J Huntingtons Dis; 2017; 6(4):363-370. PubMed ID: 29254103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.
    Mov Disord; 1996 Mar; 11(2):136-42. PubMed ID: 8684382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unawareness of motor phenoconversion in Huntington disease.
    McCusker EA; Gunn DG; Epping EA; Loy CT; Radford K; Griffith J; Mills JA; Long JD; Paulsen JS;
    Neurology; 2013 Sep; 81(13):1141-7. PubMed ID: 23966256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing Mental Health Difficulties of Persons With Huntington's Disease: Does Informant Presence Make a Difference?
    Gunn S; Maltby J; Dale M
    J Neuropsychiatry Clin Neurosci; 2020; 32(3):244-251. PubMed ID: 32102601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease.
    Zappacosta B; Monza D; Meoni C; Austoni L; Soliveri P; Gellera C; Alberti R; Mantero M; Penati G; Caraceni T; Girotti F
    Arch Neurol; 1996 Jun; 53(6):493-7. PubMed ID: 8660149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal assessment of the Unified Huntington's Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington's disease.
    Winder JY; Achterberg WP; Gardiner SL; Roos RAC
    Eur J Neurol; 2019 May; 26(5):780-785. PubMed ID: 30576046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive deficits in Huntington's disease on the Repeatable Battery for the Assessment of Neuropsychological Status.
    Duff K; Beglinger LJ; Theriault D; Allison J; Paulsen JS
    J Clin Exp Neuropsychol; 2010 Mar; 32(3):231-8. PubMed ID: 19484645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.
    Hart EP; Dumas EM; Giltay EJ; Middelkoop HA; Roos RA
    J Huntingtons Dis; 2013; 2(2):137-47. PubMed ID: 25063511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A variation of Capgras syndrome with anosognosia in Huntington's disease: a case report.
    Frankenburg FR
    Hillside J Clin Psychiatry; 1989; 11(2):121-6. PubMed ID: 2535089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emotion Evaluation and Social Inference Impairments in Huntington's Disease.
    Philpott AL; Andrews SC; Staios M; Churchyard A; Fisher F
    J Huntingtons Dis; 2016 May; 5(2):175-83. PubMed ID: 27163947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropsychological findings and depressive symptoms in patients with Huntington's disease.
    Lundervold AJ; Reinvang I
    Scand J Psychol; 1991; 32(3):275-83. PubMed ID: 1836896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benton Judgment of Line Orientation (JoLO) Test: A Brief and Useful Measure for Assessing Visuospatial Abilities in Manifest, but not Premanifest, Huntington's Disease.
    Corey-Bloom J; Gluhm S; Herndon A; Haque AS; Park S; Gilbert PE
    J Huntingtons Dis; 2016; 5(1):91-6. PubMed ID: 27003664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.